Sold as Sectral. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 16, 2026, FDA lists 4 applications for Acebutolol Hydrochloride (sold as Sectral), first approved Dec 28, 1984, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Acebutolol HCl | Part D | $4.4M | 0% | 17,532 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Preliminary Study for INFORMEDHeart Failure, Heart Failure, Diastolic · Weill Medical College of Cornell University | Phase 4 | Recruiting | Oct 18, 2022 |
| Dec 28, 1984 | SectralNDA 18917 · New molecular entity | Promius Pharma | 19 | Discontinued |
| Apr 24, 1995 | Acebutolol HydrochlorideANDA 74288 | Pharmobedient | 5 | Discontinued |
| Oct 18, 1995 | Acebutolol HydrochlorideANDA 74007 | Ani Pharms | 8 | Marketed |
| Dec 30, 1999 | Acebutolol HydrochlorideANDA 75047 | Amneal Pharm | 5 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA